+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Infanrix And Infanrix-hexa Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • PDF Icon

    Report

  • 175 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 6103959
The infanrix and infanrix-hexa market research report is one of a series of new reports that provides infanrix and infanrix-hexa market statistics, including the infanrix and infanrix-hexa industry's global market size, regional shares, competitors with an infanrix and infanrix-hexa market share, detailed infanrix and infanrix-hexa market segments, market trends and opportunities, and any further data you may need to thrive in the infanrix and infanrix-hexa industry. This infanrix and infanrix-hexa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing global immunization initiatives, rising prevalence of vaccine-preventable diseases, expanding healthcare access in emerging economies, supportive government policies and funding, and growing awareness about pediatric immunization. Major trends in the forecast period include advancements in cold chain logistics, integration with digital vaccination tracking systems, innovation in formulations, advancements in vaccine delivery technologies, and advancements in combination vaccines.

The growing number of pertussis cases is expected to drive the growth of the Infanrix and Infanrix-Hexa vaccine market. Pertussis, also known as whooping cough, is a highly contagious respiratory disease, and the prevalence of the condition has been rising due to factors such as lower vaccination rates, changes in immunity, and an increase in undiagnosed or misdiagnosed cases. As pertussis cases rise, the demand for Infanrix and Infanrix-Hexa vaccines increases since these vaccines effectively prevent the disease. For example, in October 2024, the Health Protection Surveillance Centre in Ireland reported 514 pertussis cases, a significant increase from the 18 cases in 2023, and much higher than the 7 cases in 2022 and 5 cases in 2021. This increase in pertussis cases is expected to drive the demand for these vaccines, fueling market growth.

The growth of the Infanrix and Infanrix-Hexa market is also anticipated to be influenced by rising healthcare expenditure. As healthcare spending rises, driven by factors such as an aging population, increasing healthcare needs, advancements in medical technology, and the higher costs of services and medications, more resources are allocated to healthcare services. This increased spending will support immunization efforts, thereby improving vaccine availability and facilitating the growth of the Infanrix and Infanrix-Hexa market. For example, in May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure from 2022 to 2023, compared to a 0.9% growth in the previous year. This increase in healthcare expenditure is expected to further drive the market for Infanrix and Infanrix-Hexa vaccines.

The rising number of child deaths is also expected to contribute to the growth of the Infanrix and Infanrix-Hexa vaccine market. Child death rates refer to the number of children who die under the age of 15 within a specific time frame, and the increase in child mortality is linked to factors such as malnutrition, inadequate healthcare, infectious diseases, poor hygiene, and economic challenges. The Infanrix and Infanrix-Hexa vaccines help reduce child mortality by protecting children from multiple life-threatening diseases. For instance, in May 2024, the Office for National Statistics reported that there were 2,349 infant deaths and 1,019 child deaths in 2022, an increase from the previous year’s numbers. As child mortality rates rise, the demand for vaccines such as Infanrix and Infanrix-Hexa is expected to increase, driving market growth.

The key company operating in the infanrix and infanrix-hexa market is GlaxoSmithKline plc.

North America was the largest region in the infanrix and infanrix-hexa market in 2024. The regions covered in infanrix and infanrix-hexa report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the infanrix and infanrix-hexa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Infanrix and Infanrix-hexa are vaccines designed to protect infants and young children from several serious infectious diseases. Infanrix is a vaccine that provides protection against diphtheria, tetanus, and whooping cough (pertussis), and is administered in multiple doses starting at 2 months of age to help prevent these infections. In contrast, Infanrix-hexa is a combination vaccine that provides protection against six diseases: diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b (Hib).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary patient demographics for Infanrix and Infanrix-hexa include infants, children, adolescents, and adults. Infants, referring to children under 1 year of age, are particularly protected by these vaccines, which prevent multiple infectious diseases. These vaccines are used for clinical indications such as diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib). They are distributed through various channels including hospitals, clinics, public health programs, and pharmacies, with applications in primary vaccination, booster doses, and in combination with other vaccines.

The infanrix and infanrix-hexa market consists of sales of Infanrix vaccines for diphtheria, tetanus, and whooping cough, Infanrix-hexa vaccines for diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b and combination vaccines for infants and young children to protect against multiple infectious diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Infanrix And Infanrix-hexa Market Characteristics
3. Infanrix And Infanrix-hexa Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Infanrix And Infanrix-hexa Market Trends And Strategies5. Infanrix And Infanrix-hexa Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
6. Global Infanrix And Infanrix-hexa Growth Analysis And Strategic Analysis Framework
6.1. Global Infanrix And Infanrix-hexa PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Infanrix And Infanrix-hexa Market Growth Rate Analysis
6.4. Global Infanrix And Infanrix-hexa Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
6.5. Global Infanrix And Infanrix-hexa Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
6.6. Global Infanrix And Infanrix-hexa Total Addressable Market (TAM)
7. Global Infanrix And Infanrix-hexa Pricing Analysis & Forecasts
8. Infanrix And Infanrix-hexa Market Segmentation
8.1. Global Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Infants
  • Children
  • Adolescents And Adults
8.2. Global Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Diphtheria
  • Tetanus
  • Pertussis (Whooping Cough)
  • Hepatitis B
  • Poliomyelitis
  • Haemophilus Influenzae Type B (Hib)
8.3. Global Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Hospitals
  • Clinics
  • Public Health Programs
  • Pharmacies
8.4. Global Infanrix And Infanrix-hexa Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Primary Vaccination
  • Booster Doses
  • Combination With Other Vaccines
9. Global Infanrix And Infanrix-hexa Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Infanrix And Infanrix-hexa Market Regional And Country Analysis
10.1. Global Infanrix And Infanrix-hexa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Infanrix And Infanrix-hexa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11. Asia-Pacific Infanrix And Infanrix-hexa Market
11.1. Asia-Pacific Infanrix And Infanrix-hexa Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Infanrix And Infanrix-hexa Market
12.1. China Infanrix And Infanrix-hexa Market Overview
12.2. China Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Infanrix And Infanrix-hexa Market
13.1. India Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Infanrix And Infanrix-hexa Market
14.1. Japan Infanrix And Infanrix-hexa Market Overview
14.2. Japan Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Infanrix And Infanrix-hexa Market
15.1. Australia Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Infanrix And Infanrix-hexa Market
16.1. South Korea Infanrix And Infanrix-hexa Market Overview
16.2. South Korea Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Infanrix And Infanrix-hexa Market
17.1. Western Europe Infanrix And Infanrix-hexa Market Overview
17.2. Western Europe Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Infanrix And Infanrix-hexa Market
18.1. UK Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19. Germany Infanrix And Infanrix-hexa Market
19.1. Germany Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Infanrix And Infanrix-hexa Market
20.1. France Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Infanrix And Infanrix-hexa Market
21.1. Eastern Europe Infanrix And Infanrix-hexa Market Overview
21.2. Eastern Europe Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Infanrix And Infanrix-hexa Market
22.1. North America Infanrix And Infanrix-hexa Market Overview
22.2. North America Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Infanrix And Infanrix-hexa Market
23.1. USA Infanrix And Infanrix-hexa Market Overview
23.2. USA Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24. Canada Infanrix And Infanrix-hexa Market
24.1. Canada Infanrix And Infanrix-hexa Market Overview
24.2. Canada Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Infanrix And Infanrix-hexa Market
25.1. South America Infanrix And Infanrix-hexa Market Overview
25.2. South America Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Infanrix And Infanrix-hexa Market
26.1. Middle East Infanrix And Infanrix-hexa Market Overview
26.2. Middle East Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Infanrix And Infanrix-hexa Market
27.1. Africa Infanrix And Infanrix-hexa Market Overview
27.2. Africa Infanrix And Infanrix-hexa Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Infanrix And Infanrix-hexa Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Infanrix And Infanrix-hexa Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Infanrix And Infanrix-hexa Market Competitive Landscape And Company Profiles
28.1. Infanrix And Infanrix-hexa Market Competitive Landscape
28.2. Infanrix And Infanrix-hexa Market Company Profiles
28.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
29. Global Infanrix And Infanrix-hexa Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Infanrix And Infanrix-hexa Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Infanrix And Infanrix-hexa Market32. Recent Developments In The Infanrix And Infanrix-hexa Market
33. Infanrix And Infanrix-hexa Market High Potential Countries, Segments and Strategies
33.1 Infanrix And Infanrix-hexa Market In 2029 - Countries Offering Most New Opportunities
33.2 Infanrix And Infanrix-hexa Market In 2029 - Segments Offering Most New Opportunities
33.3 Infanrix And Infanrix-hexa Market In 2029 - Growth Strategies
33.3.1 Market Trend Based Strategies
33.3.2 Competitor Strategies
34. Appendix
34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. About the Analyst
34.6. Copyright And Disclaimer

Executive Summary

Infanrix And Infanrix-hexa Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on infanrix and infanrix-hexa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for infanrix and infanrix-hexa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The infanrix and infanrix-hexa market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Patient Demographics: Infants; Children; Adolescents And Adults
2) By Clinical Indication: Diphtheria; Tetanus; Pertussis (Whooping Cough); Hepatitis B; Poliomyelitis; Haemophilus Influenzae Type B (Hib)
3) By Distribution Channel: Hospitals; Clinics; Public Health Programs; Pharmacies
4) By Application: Primary Vaccination; Booster Doses; Combination With Other Vaccines

Key Companies Profiled: GlaxoSmithKline plc

Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • GlaxoSmithKline plc